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implantation.
METHODS Sixty patients (45 men (75%), 55  7 years) with a docu-
mented single vessel type A or B1 lesion, either stable or unstable
angina without biochemical signs of myocardial infarction, were
included in this single blind randomized clinical trial. Patients were
randomized to implantation of a DES or BVS (Xience Prime or
ABSORB, respectively) in a one-to-one fashion. Approximately 1
month after percutaneous coronary intervention patients underwent
H215O PET to assess (hyperemic) MBF, cold pressor test MBF, and
CFR.
RESULTS Lesions were predominantly located in the LAD (n¼36,
60%) and less frequently in the RCA (n¼14, 23%) or Cx (n¼10, 17%).
One patient refused PET perfusion at 1 month follow-up (DES arm).
MBF of the treated myocardial territory during rest, CPT, and hyper-
emia of DES was comparable with the BVS arm (0.96  0.24 vs. 1.02 
0.28 mLmin-1g-1, p¼0.38, 1.08  0.23 vs. 1.20  0.38 mLmin-1g-1,
p¼0.16, and 3.33  0.77 vs. 3.04  0.80 mLmin-1g-1, p¼0.16,
respectively). CFR of the treated territory was signiﬁcantly lower in
the BVS arm compared to DES (3.09  0.94 vs. 3.57  0.85, p<0.05). No
signiﬁcant differences in (hyperemic) MBF, CPT, and CFR were
documented in remote areas between treatment arms. Also, a trend
toward an attenuated remote CFR was observed in the BVS treatment
arm (3.03  0.86 vs. 3.48  0.96 mLmin-1g-1, p¼0.06).
CONCLUSIONS CFR is attenuated one month after implantation of a
BVS compared with a DES, although, quantitative hyperemic MBF was
not different between both treatment arms.
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BACKGROUND The safety and performance of the current Absorb
Bioresorbable Vascular Scaffold (Absorb BVS) (Abbott Vascular, Santa
Clara, CA) has been previously established in 101 patients enrolled in
the Cohort B of the First-in-Man ABSORB trial. At 48 months, MACE
rate in Cohort B was 10.1%, with no scaffold thrombosis (ST) reported.
ABSORB EXTEND was initiated as a global, continued access, inter-
national (outside of the US) study to expand the clinical experience
with the Absorb BVS to different geographies. Of note, investigators
were allowed to treat patients with longer coronary lesions and
smaller vessels than those in the Cohort B trial, using either longer
scaffold lengths or planned overlap with the 2.5-mm and 3.0-mm
Absorb BVS.
METHODS ABSORB EXTEND is a prospective, single-arm, open-label
clinical study that enrolled 812 subjects at 56 sites. Included were
patients with lesions  28 mm in length and reference vessel diameter
of 2.0 mm - 3.3 mm (as assessed by on-line QCA or IVUS). Treatment of
a maximum of two de novo native coronary artery lesions, each in a
different epicardial vessel, was permitted.
RESULTS Interim 24-month data in the ﬁrst 450 ABSORB EXTEND
study patients has been previously presented. Among patients
included, 33% had unstable angina, 29% prior MI and 27% diabetes
mellitus. Mean RVD and mean lesion length were 2.610.35 mm and
11.614.89 mm, respectively. In these 450 patients, hierarchical
MACE, TVF and def/prob ST rates at 2 years were 6.7%, 7.4% and 1.1%,
respectively. Long-term (36-month) follow-up data will be presented
for the ﬁrst 500 patients enrolled with the aim of providing substan-
tial data on long-term safety and performance of the Absorb BVS in a
larger population of patients, including those with planned over-
lapping and dual vessel treatment.
CONCLUSIONS Long-term outcomes in approximately 500 patients at
36 months (the largest patient cohort reported at this time point to
date) from ABSORB EXTEND will provide further insight into the
safety and performance of the Absorb BVS.
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BACKGROUND The aim of this single center observational study was
to investigate the feasibility of bioresorbable vascular scaffold (BVS)
in treatment in-stent restenosis lesions. In stent restenosis is still a
relatively common problem in daily practice. Existing solutions were
not fully effective so far. The use of drug-eluting stents (DES) is
related with increased thrombosis risk, also drug-eluting balloon has
disadvantage because the eluted-drug stays in the arterial wall only
for few weeks, which is not sufﬁcient to eliminate the risk of reste-
nosis. Bioresorbable scaffolds could be possible solution of this issue.
The BVS has a number of proposed advantages over current metallic
stent technology which could be helpful in providing short-term
vessel scaffolding and capability of prolonged drug delivery.
METHODS Between October 2013 and January 2015, 53 Patients (61
lesions) were enrolled in single arm prospective open label study in
which in stent restenosis lesions was suitable for BVS implantation.
Primary endpoints were procedural success of deployment of the BVS
at the target lesion and absence of in-hospital major adverse events
(death, Q-wave myocardial infarction, stroke or any repeat target
lesion revascularization). The mean patient age was 6412 years and
78% patients were male, 93% suffered from hypertension and 31%
from diabetes. PCI procedures were performed in 87% patients pre-
senting with stable CAD and 13% with acute coronary syndrome. Ac-
cording to the angiographic ISR pattern 45% lesions were focal and
55% were diffuse, the majority of the lesions was post DES ISR (79%).
Procedural OCT evaluation was performed in all lesions (100%) before
and post-BVS implantation. Estimate the size of the BVS was made on
the basis of the IVUS examination just after ﬁrst balloon predilatation.
Lesion pre-dilatation was mandatory and post dilatation was needed
in 92% of cases. After 6 month of BVS implantation clinical evaluation
was made, the next 6 month patients had performed control angiog-
raphy with OCT.
RESULTS Procedural success was obtained in all cases. No in-hospital
clinical events and intra-procedural or acute BVS-in-stent thrombosis
were reported. Mean BVS implanted length was 30,5 mm. A number of
1.6 stents were implanted per lesion. At a median of 6 months follow
up 2 clinically-driven TLR ( 3.8% per patient) were reported due to
recurrent ISR at the BVS-in-stent implantation site. No cardiac death,
Q-wave MI occurred at follow-up. Re-evaluation by angiography with
OCT will be obtained in next 12 months follow-up after procedure.
CONCLUSIONS The results of our study suggest that BVS is safe and
technically feasible for the treatment of ISR in patients presenting
with both stable CAD and ACS with reasonable midterm outcomes.
Moreover, follow-up revealed a very low rate of adverse events in
patients treated by BVS implantation in the context of treatment of in-
stent restenosis.
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BACKGROUND Bioresorbable everolimus-eluting scaffolds (BVS) and
the Pt-Cr everolimus-eluting stent with abluminal bioabsorbable
polymer (Synergy) have shown positive clinical results in trials.
However, there are important differences in the respective platforms
which could impact on clinical performance during implantation.
